NMN vs NR: Comparing NAD+ Precursor Bioavailability and Research Evidence

NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) are the two most studied NAD+ precursors, differing in their biosynthetic routes, bioavailability characteristics, tissue distribution, and clinical evidence volume.

The NAD+ Biosynthetic Pathway

The salvage pathway to NAD+:

• NR → NMN: via NR kinases (NRK1, NRK2) — requires one enzymatic step
• NMN → NAD+: via NMNAT enzymes (NMNAT1, 2, 3) — one more enzymatic step

NMN is one step closer to NAD+ than NR. Early researchers suggested this might give NMN a kinetic advantage. However, NMN as a nucleotide has poor passive membrane permeability — requiring the Slc12a8 intestinal transporter (recently characterised) or extracellular dephosphorylation to NR before cellular uptake.

Bioavailability: The Published Data

[NR](/peptides/nr-nicotinamide-riboside) — Trammell SA et al. (*Nature Communications*, 2016): isotope-labelled NR in humans tracked as NR, NMN, Nam, and methylated metabolites in blood. Blood NAD+ increased 2.7-fold above baseline at 8 hours post-dose with 1000 mg NR.

[NMN](/peptides/nmn-nicotinamide-mononucleotide) — Yoshino M et al. (*Cell Metabolism*, 2021): 250 mg NMN daily for 10 weeks raised blood NAD+ and specifically improved skeletal muscle NAD+ metabolomics. Irie J et al. (2020): plasma NMN appeared within 10 minutes of 500 mg oral NMN, suggesting extremely rapid absorption or conversion.

Neither compound has demonstrated substantially superior bioavailability in head-to-head human studies, though tissue distribution may differ.

Human Trial Evidence

NR:

• Martens CR et al. (*Nature Communications*, 2018): 1g NR/day for 6 weeks in healthy older adults → blood NAD+ increased 60%; systolic BP reduced ~4 mmHg in the stage-1 hypertension subset
• Dollerup OL et al. (*Nature Communications*, 2018): 2g NR/day in obese men for 12 weeks → NAD+ raised significantly; no significant effect on insulin sensitivity (primary endpoint)

[NMN](/peptides/nmn-nicotinamide-mononucleotide):

• Yoshino M et al. (*Cell Metabolism*, 2021): 250 mg/day in 25 postmenopausal prediabetic women → significantly improved skeletal muscle insulin signalling — compelling but small-scale
• Pencina MJ et al. (*Nature Aging*, 2023): 1000 mg/day in 30 healthy older adults → raised NAD+ ~38%; improved walking speed and muscle function at 28 days vs placebo

Key Differences

Both reliably raise blood and tissue NAD+ in humans. Neither has established clear clinical superiority over the other, though NMN shows advantages in skeletal muscle NAD+ specifically.

NMN and NR are dietary supplements in the US. Not approved drugs. Do not use for treatment of disease.

<!-- deep-links-v1 -->

Related NAD+ and Longevity Peptides

NMN and NR are NAD+ precursors, but the longevity research space includes peptide-based approaches that operate on overlapping biology. NAD+ (nicotinamide adenine dinucleotide), the direct coenzyme target of both precursors, is itself the comparator endpoint in bioavailability studies. Humanin, encoded by the mitochondrial genome, shows protective effects in the same metabolic and aging pathways that NAD+ supports. SHLP-2 (Small Humanin-Like Peptide 2) similarly protects mitochondrial function in beta-cells and aged tissue. FOXo4-DRI targets the senescent cell population whose accumulation is mechanistically linked to declining NAD+ metabolism. Endoluten, the pineal bioregulator, regulates circadian melatonin signaling — a pathway that intersects with NAD+-dependent SIRT1 deacetylase activity.